ClinicalTrials.gg
Active, not recruitingNCT05054140CALLIPERUpdated Apr 29, 2024

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

A Phase 2 interventional study of IMU-838 and Placebo matching IMU-838 in Multiple Sclerosis, sponsored by Immunic AG. Active, not recruiting at 73 sites in 12 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by Immunic AG · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 66 studies in Multiple Sclerosis with a site in Bulgaria — 2 open to participants now, 15 under way, 12 of them phase 3. Multiple Sclerosis · Bulgaria.

Planned enrollment
43rd of 64
450 · median 707
Started
2021
with 3 others
Phase 2
15 of 66
none open now
Primary completion
2025-01
later than 3 of 14 live
Registered
56th of 66
by date
Lead sponsor
3 of 66
Immunic AG

Among the 66 studies in Multiple Sclerosis with a site in Bulgaria, this one is the 43rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 4 that started in 2021, is one of 15 in phase 2, reaches primary completion later than 3 of the 14 other live ones, and was the 56th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 66 studies in Multiple Sclerosis with a site in Bulgaria are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Multiple Sclerosis with a site in Bulgaria, or all of them as a file.
02

Study summary

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER

Read the detailed description

This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU838 in adult patients with PMS. The study will consist of the following periods:

Screening Period: Approximately 28 days Main Treatment Period: Up to 120 weeks (approximately 2 years) Open Label Extension Period: Up to approximately 8 years

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • Progressive Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, age 18 to 65 years (inclusive).
  • EDSS score at screening between 3.0 to 6.5 (both inclusive)
  • No evidence of relapse in the last 24 months before randomization, AND Patients diagnosed according to 2017 revised McDonald Criteria 1 and the 2013 revised classification of disease courses 2 as either

    1. SPMS inpatients showing evidence of Gd+MRI lesions (active SPMS) or without Gd+MRI lesions (non-active SPMS) in the last 12 months, OR
    2. PPMS
  • Willingness and ability to comply with the protocol.
  • Written given by the patient before the beginning of any study-related procedure.
  • Documented evidence of disability progression not temporarily related to a relapse in the last 24 months before randomization, adjudicated by a central independent reviewer

Exclusion criteria

Exclusion Criteria:

  • Any disease other than MS that may better explain the signs and symptoms, including a history of complete transverse myelitis.
  • Clinical signs or presence of laboratory findings suggestive for neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-associated encephalomyelitis (i.e.,presence of anti-NMO [aquaporin-4] antibodies or anti-MOG antibodies).
  • Previous or current use of MS treatments lifelong, or within a pre-specified time period.
  • Use of any product within 8 weeks or 5 the respective PK half- life before the date of , whichever is longer, and throughout the study.For some investigational products, prolonged biological effects beyond 8 weeks should be considered.
  • Positive test for severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) within14 days before randomization. In case of known SARS-CoV-2 infection, patients should be randomized no earlier than 14 days after 2 consecutive negative tests confirming virus negative status.The screening period can be extended for these patients to accommodate the required virus negativity.
  • Positive IFN-gamma release assay (IGRA) for Mycobacterium tuberculosis at SV1.
  • Positive virus (HBV) surface antigen, hepatitis B core antibody, positive virus (HCV) antibody, and/or -antigen-antibody test at SV1.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    IMU-838

    IMU-838 as tablet; Administration: Oral - daily

    Drug: IMU-838

  • Placebo comparator
    Placebo

    Matching placebo as tablet; Administration: Oral - daily

    Drug: Placebo matching IMU-838

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of IMU-838 versus placebo

    Annualized rate of percent brain volume change (PBVC) during MT period

    Time frame: 120 weeks

Secondary outcomes

  1. Efficacy of IMU-838 versus placebo

    Annualized rate of change in brain parenchymal fraction (BPF) during MT Period

    Time frame: 120 weeks

  2. Efficacy of IMU-838 versus placebo in terms of disability worsening

    Time to 24-week confirmed disability worsening based on expanded disability status scale (EDSS) during MT Period

    Time frame: 120 weeks

Other outcomes

  1. Safety IMU-838 versus placebo

    Adverse events (AEs) and serious AEs (SAEs) during MT Period

    Time frame: 120 weeks

07

Study locations

73 sites
  • Dr. Sonia Kalirao
    Coral Springs, Florida 33067, United States
  • Collier Neurologic Specialists
    Naples, Florida 34105, United States
  • Prof. James Scott
    Ormond Beach, Florida 32174, United States
  • Shepherd Center
    Atlanta, Georgia 30309, United States
  • Consultants in Neurology, Ltd.
    Northbrook, Illinois 60062, United States
  • Dr. Daniel Becker
    Lutherville, Maryland 21093, United States
  • Dr. Mirela Cerghet
    Detroit, Michigan 48202, United States
  • University of New Mexico (UNM), MS Specialty Clinic
    Albuquerque, New Mexico 87106, United States
  • MHAT Pulse
    Blagoevgrad, 2700, Bulgaria
  • MHAT"Heart and Brain" EAD
    Burgas, Bulgaria
  • Dr. Maya Danovska
    Pleven, 5800, Bulgaria
  • Dr. Plamen Bozhinov
    Pleven, 5804, Bulgaria
  • UMHAT Pulmed
    Plovdiv, Bulgaria
  • Dr. Rositsa Krasteva
    Ruse, 7003, Bulgaria
  • Dr. Nikolay Georgiev
    Shumen, 9700, Bulgaria
  • MHAT Shumen
    Shumen, 9705, Bulgaria
  • Dr. Ivan Milanov
    Sofia, 1113, Bulgaria
  • MHAT Lyulin
    Sofia, 1336, Bulgaria
  • Dr. Rosen Ikonomov
    Sofia, 1408, Bulgaria
  • Dr. Penko Shotekov
    Sofia, 1431, Bulgaria
  • UMHAT Alexandrovska
    Sofia, 1431, Bulgaria
  • Dr. Kana Prinova
    Sofia, 1606, Bulgaria
  • Dr. Kosta Kostov
    Sofia, 1606, Bulgaria
  • MHAT Sveta Sofia
    Sofia, Bulgaria
  • UMHATSM N.I.Pirogov
    Sofia, Bulgaria
  • UMHAT Prof. Stoyan Kirkovich
    Stara Zagora, Bulgaria
  • Dr. Ara Kaprelyan
    Varna, 9010, Bulgaria
  • Montreal Neurological Inst.
    Montréal, H3A 2B4, Canada
  • The Ottawa Hospital Research Institute
    Ottawa, K1H 8L6, Canada
  • Fakultni nemocnice
    Hradec Králové, Czechia
  • Klinik und Poliklinik für Neurologie, Universitätsklinikum Dresden
    Dresden, 01307, Germany
  • Neuro Centrum Science GmbH
    Erbach, Germany
  • Universitätsklinikum Hamburg Eppendorf
    Hamburg, 20251, Germany
  • Datamed GmbH
    Köln, 50935, Germany
  • Dr. Stanislav Groppa
    Chisinau, 2004, Moldova, Republic of
  • Dr. Mihail Gavriliuc
    Chisinau, 2028, Moldova, Republic of
  • Dr. Olesea Odainic
    Chisinau, 2028, Moldova, Republic of
  • Dr. Eva Strijibis
    Amsterdam, 1081BT, Netherlands
  • Alrijne ziekenhuis
    Leiderdorp, Netherlands
  • Dr. Ana Doneva Skopje 1000
    Skopje, 1000, North Macedonia
  • Dr. Milcho Demerdziev
    Skopje, 1000, North Macedonia
  • Dr. Tatjana Boshkova
    Skopje, 1000, North Macedonia
  • Dr. Robert Bonek
    Bydgoszcz, 85-796, Poland
  • Dr. Maciej Maciejowski
    Katowice, 40-571, Poland
  • Dr. Janusz Zbrojkiewicz
    Katowice, 40-686, Poland
  • Dr. Elzbieta Jasinska
    Kielce, 25-726, Poland
  • Indywidualna Praktyka Lekarska Prof. Rejdak
    Lublin, 20-016, Poland
  • Dr. Marcin Nastaj
    Lublin, 20-640, Poland
  • Instytut Zdrowia
    Oświęcim, Poland
  • Dr. Justyna Hryniewicz
    Plewiska, 62-064, Poland
  • Clinical Research Center
    Poznań, Poland
  • EMC PL Certus
    Poznań, Poland
  • NZOZ "Neuro-kard"
    Poznań, Poland
  • Dr. Marcin Ratajczak
    Szczecin, 70-111, Poland
  • Warszawska Klinika
    Warsaw, Poland
  • EMC Instytut Medyczny
    Wrocław, Poland
  • Dr. Adriana Dulamea
    Bucharest, 22328, Romania
  • Dr. Lacramioara Perju-Dumbrava
    Cluj-Napoca, 400013, Romania
  • Clinical Hospital Center Zemun
    Belgrade, Serbia
  • Military Medical Academy
    Belgrade, Serbia
  • Klinicki Centar Kragujevac
    Kragujevac, 34000, Serbia
  • Clinical center of Vojvodina
    Novi Sad, Serbia
  • Chernivtsi Medical Hospital
    Chernivtsi, Ukraine
  • Dr. Olena Moroz
    Dnipro, 49000, Ukraine
  • Dr. Pavlo Khaitov
    Dnipro, 49128, Ukraine
  • Dr. Tamara Mishchenko
    Kharkiv, 61068, Ukraine
  • Dr. Oleksandr Doroschenko
    Krykhivtsi, 76493, Ukraine
  • Dr. Larysa Sokolova
    Kyiv, 03037, Ukraine
  • Dr. Galusha
    Kyiv, 04106, Ukraine
  • Dr. Olga Shulga
    Lutsk, 43005, Ukraine
  • Dr.Tetyana Nehrych
    Lviv, 79010, Ukraine
  • Dr. Svitlana Skhrobot
    Ternopil, 46024, Ukraine
  • Dr. Sergii Moskovko
    Vinnytsya, 21050, Ukraine
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Jan 2025, 39 months after the start.

Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 39 months is above that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2021
First posted
Sep 23, 2021
StartActual
Sep 30, 2021
Primary completionEst.
Jan 7, 2025
CompletionEst.
Jan 7, 2025
Last update
Apr 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05054140
Lead sponsor
Immunic AG
Responsible party
Sponsor
First posted
Sep 23, 2021
Start date
Sep 30, 2021
Primary completion
Jan 7, 2025 (estimated)
Completion
Jan 7, 2025 (estimated)
Last update
Apr 29, 2024

Study contacts

Robert J. Fox, MD
principal investigator · Mellen Center for MS, Neurological Institute, Cleveland Clinic, Ohio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vidofludimus-calcium

Start the discussion